Filana Therapeutics Q3 2026 net loss narrows to $10.73 million

Filana Therapeutics’ third-quarter 2026 net loss narrowed year over year to $10.73 million. Cash was $47 million at September 30, and the company projected year-end cash and cash equivalents of $38 million to $42 million.